Compare Stocks: ADXN, AYTU, TXMD, and PLRZ

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$5.95 +2.6%	$6.05	$5.04 ▼ $12.05	$7.32M	1.5	4,854 shs	2,107 shs
AYTU Aytu BioPharma	$2.38 +0.8%	$2.19	$1.65 ▼ $3.07	$25.54M	0.25	52,235 shs	30,253 shs
PLRZ Polyrizon	$11.33 -2.2%	$12.82	$2.88 ▼ $18.20	$23.57M	-1.5	62,596 shs	5,421 shs
TXMD TherapeuticsMD	$2.07	$2.04	$0.99 ▼ $2.95	$23.95M	0.61	50,386 shs	14,292 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	0.00%	-0.61%	-12.21%	-17.36%	-29.31%
AYTU Aytu BioPharma	0.00%	+5.83%	+4.89%	-3.28%	-0.42%
PLRZ Polyrizon	0.00%	-2.89%	-25.43%	-32.23%	+65.53%
TXMD TherapeuticsMD	0.00%	+1.97%	+3.50%	+5.61%	+94.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$5.95 +2.6%	$6.05	$5.04 ▼ $12.05	$7.32M	1.5	4,854 shs	2,107 shs
AYTU Aytu BioPharma	$2.38 +0.8%	$2.19	$1.65 ▼ $3.07	$25.54M	0.25	52,235 shs	30,253 shs
PLRZ Polyrizon	$11.33 -2.2%	$12.82	$2.88 ▼ $18.20	$23.57M	-1.5	62,596 shs	5,421 shs
TXMD TherapeuticsMD	$2.07	$2.04	$0.99 ▼ $2.95	$23.95M	0.61	50,386 shs	14,292 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	0.00%	-0.61%	-12.21%	-17.36%	-29.31%
AYTU Aytu BioPharma	0.00%	+5.83%	+4.89%	-3.28%	-0.42%
PLRZ Polyrizon	0.00%	-2.89%	-25.43%	-32.23%	+65.53%
TXMD TherapeuticsMD	0.00%	+1.97%	+3.50%	+5.61%	+94.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXN Addex Therapeutics	1.00	Sell	N/A	N/A
AYTU Aytu BioPharma	2.00	Hold	$10.75	351.68% Upside
PLRZ Polyrizon	1.00	Sell	N/A	N/A
TXMD TherapeuticsMD	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ADXN, AYTU, TXMD, and PLRZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/15/2026	AYTU Aytu BioPharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/13/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/6/2026	ADXN Addex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/6/2026	AYTU Aytu BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/2/2026	TXMD TherapeuticsMD	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/26/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/11/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/11/2026	AYTU Aytu BioPharma	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$14.00 ➝ $14.50
5/21/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/11/2026	AYTU Aytu BioPharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXN Addex Therapeutics	$210K	34.85	N/A	N/A	$4.67 per share	1.27
AYTU Aytu BioPharma	$66.38M	0.38	$0.38 per share	6.29	$2.11 per share	1.13
PLRZ Polyrizon	N/A	N/A	N/A	N/A	$13.05 per share	N/A
TXMD TherapeuticsMD	$3.02M	7.93	$0.05 per share	44.37	$2.32 per share	0.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXN Addex Therapeutics	-$8.12M	-$5.94	N/A	N/A	N/A	N/A	-134.76%	-106.00%	8/24/2026 (Estimated)
AYTU Aytu BioPharma	-$13.56M	-$4.58	N/A	9.52	N/A	-60.17%	-69.93%	-13.25%	9/29/2026 (Estimated)
PLRZ Polyrizon	-$3.34M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	-$570K	$0.06	34.50	N/A	N/A	5.34%	0.32%	0.23%	8/17/2026 (Estimated)

Latest ADXN, AYTU, TXMD, and PLRZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/17/2026	Q2 2026	TXMD TherapeuticsMD	-$6.1250	N/A	N/A	N/A	$19.77 million	N/A
5/13/2026	Q3 2026	AYTU Aytu BioPharma	-$0.4433	-$0.53	-$0.0867	-$0.53	$12.05 million	$12.41 million
5/12/2026	Q1 2026	TXMD TherapeuticsMD	-$6.1250	$0.01	+$6.1350	$0.01	$19.77 million	$0.72 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXN Addex Therapeutics	N/A	0.97	0.97
AYTU Aytu BioPharma	0.27	1.12	1.00
PLRZ Polyrizon	N/A	29.03	29.03
TXMD TherapeuticsMD	N/A	3.11	3.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXN Addex Therapeutics	16.14%
AYTU Aytu BioPharma	33.49%
PLRZ Polyrizon	N/A
TXMD TherapeuticsMD	30.74%

Insider Ownership

Company	Insider Ownership
ADXN Addex Therapeutics	15.00%
AYTU Aytu BioPharma	4.90%
PLRZ Polyrizon	N/A
TXMD TherapeuticsMD	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXN Addex Therapeutics	30	1.23 million	1.05 million	Not Optionable
AYTU Aytu BioPharma	160	10.73 million	10.21 million	Not Optionable
PLRZ Polyrizon	N/A	2.08 million	N/A	N/A
TXMD TherapeuticsMD	420	11.57 million	11.38 million	Optionable

ADXN, AYTU, TXMD, and PLRZ Headlines

Recent News About These Companies

TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gains

June 5, 2026 | marketwatch.com

TherapeuticsMD Reports Quarterly Profit, Evaluates Strategic Alternatives

May 12, 2026 | tipranks.com

TherapeuticsMD Announces First Quarter 2026 Financial Results

May 12, 2026 | businesswire.com

TherapeuticsMD Inc. stock outperforms competitors on strong trading day

April 6, 2026 | marketwatch.com

TherapeuticsMD Narrows 2025 Loss, Advances Royalty Strategy

April 2, 2026 | theglobeandmail.com

TherapeuticsMD Explains Brief Delay In Annual Filing

April 1, 2026 | tipranks.com

TherapeuticsMD Announces Full Year 2025 Financial Results

March 30, 2026 | finance.yahoo.com

TherapeuticsMD Announces Full Year 2025 Financial Results

March 30, 2026 | businesswire.com

TherapeuticsMD (NASDAQ:TXMD) Director Tommy Thompson Buys 8,400 Shares

December 30, 2025 | insidertrades.com

TherapeuticsMD approves key proposals at annual meeting

December 16, 2025 | msn.com

TherapeuticsMD: Q3 Earnings Snapshot

November 13, 2025 | timesunion.comT

TherapeuticsMD Reports Q3 2025 Financial Results

November 13, 2025 | msn.com

TherapeuticsMD Announces Third Quarter 2025 Financial Results

November 12, 2025 | businesswire.com

TherapeuticsMD Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

TherapeuticsMD: Q2 Earnings Snapshot

August 12, 2025 | finance.yahoo.com

TherapeuticsMD Announces Second Quarter 2025 Financial Results

August 12, 2025 | businesswire.com

TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gains

July 16, 2025 | marketwatch.com

Marlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street Journal

June 29, 2025 | wsj.com

Mayne Pharma Files Legal Complaint Against TherapeuticsMD

June 1, 2025 | tipranks.com

TherapeuticsMD Announces First Quarter 2025 Financial Results

May 13, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXN, AYTU, TXMD, and PLRZ Company Descriptions

Addex Therapeutics NASDAQ:ADXN

$5.95 +0.15 (+2.59%)

As of 03:14 PM Eastern

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Aytu BioPharma NASDAQ:AYTU

$2.38 +0.02 (+0.85%)

As of 04:00 PM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Polyrizon NASDAQ:PLRZ

$11.33 -0.26 (-2.24%)

As of 04:00 PM Eastern

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

TherapeuticsMD NASDAQ:TXMD

$2.07 0.00 (0.00%)

As of 04:00 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADXN, AYTU, TXMD, and PLRZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADXN, AYTU, TXMD, and PLRZ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADXN, AYTU, TXMD, and PLRZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXN, AYTU, TXMD, and PLRZ Company Descriptions

Addex Therapeutics NASDAQ:ADXN

Aytu BioPharma NASDAQ:AYTU

Polyrizon NASDAQ:PLRZ

TherapeuticsMD NASDAQ:TXMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADXN, AYTU, TXMD, and PLRZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADXN, AYTU, TXMD, and PLRZ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADXN, AYTU, TXMD, and PLRZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXN, AYTU, TXMD, and PLRZ Company Descriptions

Addex Therapeutics NASDAQ:ADXN

Aytu BioPharma NASDAQ:AYTU

Polyrizon NASDAQ:PLRZ

TherapeuticsMD NASDAQ:TXMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools